Home  »  Companies   »  Selected Notes From Wall Street Analysts On BioSpe...

Selected Notes From Wall Street Analysts On BioSpecifics Technologies Corp. (BSTC)

On Monday, shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) marked $88.69 per share versus a previous $61.02 closing price. With having a 45.35% gain, an insight into the fundamental values of BioSpecifics Technologies Corp., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. BSTC showed a rise of 55.76% within its YTD performance, with highs and lows between $42.00 – $69.73 during the period of 52 weeks, compared to the simple moving average of 50.65% in the period of the last 200 days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


H.C. Wainwright equity researchers changed the status of BioSpecifics Technologies Corp. (NASDAQ: BSTC) shares to a “Buy” rating in the report published on July 7th, 2020. Other analysts, including H.C. Wainwright, also published their reports on BSTC shares. H.C. Wainwright repeated the rating from the previous report, marking BSTC under “Buy” rating, in the report published on November 13th, 2017. Additionally, BSTC shares got another “Buy” rating from Rodman & Renshaw, setting a target price of $60 on the company’s shares, according to the report published in March 8th, 2016. On July 16th, 2015, MLV & Co Initiated an Buy rating and increased its price target to $76. On the other hand, MKM Partners Reiterated the “Buy” rating for BSTC shares, as published in the report on November 11th, 2014. MKM Partners seems to be going bullish on the price of BSTC shares, based on the price prediction for BSTC, indicating that the shares will jump from $28 to $38, giving the shares “Buy” rating based on their report from August 12th, 2014. Another “Buy” rating came from MKM Partners, providing a prediction for $38 price target according to the report published in January 9th, 2014.

[bold-text]BioSpecifics Technologies Corp. (BSTC) Analysis[/bold-text]

The present dividend yield for BSTC owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -56.20%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of BioSpecifics Technologies Corp. (BSTC) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 14.60% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 29.20 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while BSTC is currently recording an average of 31.91K in volumes. The volatility of the stock on monthly basis is set at 4.04%, while the weekly volatility levels are marked at 4.05%with 43.05% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $100.00, indicating growth from the present price of $88.69, which can represent yet another valuable research and analysis points that can help you decide whether to invest in BSTC or pass.

[bold-text]What to Look for When Analyzing BioSpecifics Technologies Corp. Shares?[/bold-text]

BioSpecifics Technologies Corp. (BSTC) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare BSTC shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of 35.79 for BioSpecifics Technologies Corp., while the value 17.63 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value 2.48 is supported by the yearly EPS growth of 21.70%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 2.90%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 67.20% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

[bold-text]Are Institutional Investors Increasing Stakes in BSTC Shares?[/bold-text]

It appears that more than several institutional investors and hedge funds decided to increase stakes in BSTC in the recent period. That is how Renaissance Technologies LLC now has an increase position in BSTC by 0.59% in the first quarter, owning 543356 shares of BSTC stocks, with the value of $28.71 million after the purchase of an additional 3,200 shares during the last quarter. In the meanwhile, Russell Investment Management LLC also increased their stake in BSTC shares changed 12.35% in the first quarter, which means that the company now owns 427430 shares of company, all valued at $22.58 million after the acquisition of additional 46,997 shares during the last quarter.

BlackRock Fund Advisors acquired a new position in BioSpecifics Technologies Corp. during the first quarter, with the value of $21.41 million, and Janus Capital Management LLC increased their stake in the company’s shares by 7.84% in the first quarter, now owning 21,722 shares valued at $15.79 million after the acquisition of the additional 298909 shares during the last quarter. In the end, The Vanguard Group, Inc. increased their position by 1.71% during the first quarter, now owning 293387 BSTC shares, now holding the value of $15.5 million in BSTC with the purchase of the additional 24,041 shares during the period of the last quarter. At the present, 67.20% of BSTC shares are in the ownership of institutional investors.

Leave a Comment

Your email address will not be published.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam